

NOXXON PHARMA AG TO PRESENT AT BIO CEO & INVESTOR CONFERENCE 2007 IN NEW YORK

Berlin, Germany, February 09, 2007 -- NOXXON Pharma AG (NOXXON), the leader in Spiegelmer® therapeutics, will present at the Biotech Industry Organization BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City.

In a thirty minute presentation Chief Executive Officer Dr. Sven Klussmann will provide a corporate overview of NOXXON, including the current status of development of the company's lead compounds. The presentation will take place at 12:45 PM (US EST) on February 14th in the Waldorf Astoria's Duke of Windsor room.

About the event:

The BIO CEO & Investor Conference is the world's leading biotechnology industry organization's forum and assembles senior level industry executives and key members of the investment community to explore investment and business development opportunities. For more information or a schedule of presentations visit: <http://ceo.bio.org>.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the biggest and best protected patent portfolio in the industry, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

General contact:

Esther Hildebrandt

NOXXON Pharma AG

Max-Dohrn-Strasse 8-10

10589 Berlin, Germany

Phone: + 49 30 72 62 47 0

FAX: + 49 30 72 62 47 225

Email: ehildebrandt@noxxon.net